BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.86 USD
+0.04 (5.48%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.86 0.00 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BCTX 0.86 +0.04(5.48%)
Will BCTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BCTX
BriaCell Quadruples Progression Free Survival (PFS) in Patient with ?Eye-Bulging? Metastatic Breast Cancer
BriaCell Touts Breakthrough in Breast Cancer Survival
BriaCell reports 'significantly higher' PFS for patient in study of Bria-IMT
BCTX Stock Earnings: BriaCell Therapeutics Beats EPS for Q3 2024
BriaCell Subsidiary BriaPro Releases Financial Reports